Fierce Pharma

SEPTEMBER 18, 2023

. | Already approved as an injection to reduce wrinkles in the forehead and around the eyes, AbbVie's Botox is in position to expand its cosmetic uses to the moderate to severe form of platysma prominence, a condition which causes muscle bands to protrude from the neck.

Botox 105

Botox Cosmetics Trials 105

XTalks

SEPTEMBER 14, 2022

Daxxify was FDA-approved for similar cosmetic purposes as Botox and other neuromodulators like Dysport and Xeomin. Many people choose to undergo non-invasive cosmetic procedures to prevent or reduce the appearance of signs of aging. Daxxify is effective, as safe as competitors, and has been well tolerated in clinical trials.

Botox 98

Botox FDA Approval Cosmetics Clinical Trials 98

The Pharma Data

JUNE 18, 2021

June 8, 2021 /PRNewswire/ — Allergan Aesthetics, an AbbVie company (NYSE: ABBV ), is changing the way BOTOX ® Cosmetic, the #1 selling neurotoxin treatment 1 , is connecting with consumers. “BOTOX ® Cosmetic is honoring and celebrating the dynamic people who use our products. IRVINE, Calif.

Botox 52

Botox Cosmetics Doctors Doctor 52

The Pharma Data

APRIL 30, 2021

Global Botox Cosmetic net revenues were $477 million , an increase of 44.7 Global Botox Therapeutic net revenues were $532 million , an increase of 7.0 The positive CHMP opinion is based on data from the VIALE-A and M14-358 trials and represents the third positive CHMP opinion for an extension of indications for Venclyxto.

Botox 40

Botox Production Development Cosmetics 40

XTalks

JULY 5, 2022

Common anti-aging procedures include Botox or dermal fillers, which can reduce the appearance of wrinkles, sagging and increase volume in the face where desired. XTALKS WEBINAR: Diversity and Inclusion in Clinical Trials — Practical Steps for Patient Recruitment Strategies.

Cosmetics 98

Cosmetics Clinical Trials Clinical Trials Botox 98

The Pharma Data

AUGUST 1, 2021

Global Botox Therapeutic net revenues were $603 million, an increase of over 100.0 Global Botox Cosmetic net revenues were $584 million, an increase of over 100.0 to $6.14; Raises 2021 Adjusted Diluted EPS Guidance Range from $12.37 Global net revenues from the neuroscience portfolio were $1.459 billion, an increase of 98.8

Botox 52

Botox Cosmetics Trials Clinical Trials 52

The Pharma Data

FEBRUARY 4, 2021

– Full-Year Global Net Revenues from the Aesthetics Portfolio Were $2.590 Billion; Global Botox Cosmetic Net Revenues Were $1.112 Billion. Global Botox Cosmetic net revenues were $493 million , an increase of 9.1 Global Botox Therapeutic net revenues were $567 million , a decrease of 1.0 Recorded a $4.7

Botox 52

Botox Production Sales Cosmetics 52